Rankia Colombia Rankia Argentina Rankia Brasil Rankia Chile Rankia Czechia Rankia Deutschland Rankia España Rankia France Rankia Indonesia Rankia Italia Rankia Magyarország Rankia México Rankia Netherlands Rankia Perú Rankia Polska Rankia Portugal Rankia Romania Rankia Türkiye Rankia United Kingdom Rankia USA
Acceder

Farmas USA

135K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
10.462 / 16.979
#83689

Re: Farmas USA

OCAT

Se acabó lo que se daba. Tender offer finalizada

“The Offer and withdrawal rights expired as scheduled at 5:00 p.m., New York City time, February 9, 2016. The Offer was not extended. The Depositary has advised that, as of the expiration of the Offer, 22,675,963 Shares, representing approximately 53.6% of the Shares issued and outstanding as of the expiration of the Offer, had been validly tendered and not validly withdrawn pursuant to the Offer. The number of Shares tendered satisfies the Minimum Condition. As the Minimum Condition and each of the other conditions of the Offer have been satisfied, Purchaser has accepted for payment all Shares that were validly tendered and not validly withdrawn pursuant to the Offer.

Following expiration of the Offer and acceptance for payment of the Shares, the Purchaser had ownership sufficient to effect the Merger under Section 251(h) of the DGCL without a vote of stockholders of Ocata. Accordingly, the Purchaser has effected the Merger in which the Purchaser merged with and into Ocata, with Ocata surviving the Merger and continuing as an indirect wholly-owned subsidiary of Astellas. In the Merger, each Share outstanding (other than Shares accepted for payment in the Offer, Shares held by Astellas or the Purchaser or Shares for which an Ocata stockholder has properly exercised appraisal rights under Delaware law) was cancelled and converted into the right to receive a price per Share equal to the Offer Price. The Shares ceased to trade on the NASDAQ Global Market prior to the opening of business on February 10, 2016, and Ocata has requested that the NASDAQ Global Market file a Notification of Removal from Listing and/or Registration under Section 12(b) of the Exchange Act on Form 25 to delist and deregister the Shares.”

#83691

Re: Farmas USA

yo lo tenía claro desde el primer día ya se lo comentaba a anaramos en privado, engullida a buen precio, si falla es una inversión perdida razonable y si triunfa pelotazo pelotazo.

las bios necesitaban un castañazo, hay mucho humo dentro del sector, pero esta zona parece razonable para volver a entrar en un sector de futuro seguro y que volvera a dar pasta si se acierta en la elección, claro está.

#83693

Re: Farmas USA

NVAX

Qué bien estaría, si esto no se tuerce, acabar sentados hoy encima del 5 :))

#83694

Re: Farmas USA

ADXS gracias Framus. Yo no estoy dentro. La raya que yo comentaba ayer:

#83695

Re: Farmas USA

El otro día era CELG... hoy turno para GILD. Eso sí, GILD con su Engerix-B para hepatitis B tiene más sentido que CELG (que en realidad no parecía tener ninguno). En todo caso el tal Bret Jensen es un perma-bullish de DVAX, llueva o haga sol, caigan chuzos de punto o florezcan los cerezos, DVAX es simplemente maravilloso!

De momento me quedo con la realidad, BLA para finales de marzo y 6 meses para que la FDA dé o no su visto bueno para comercializar Heplisav. Más allá de eso...pues bueno, si hay buyout pues fantástico, claro! Pero de momento al pozo como la mayoría :((

DVAX

Edito: el Engerix-B es de GSK no de GILD, me he colao!

#83696

Re: Farmas USA

Hoy están subiendo a la vez todos los valores de mi cartera, incluida NVAX y THLD.....esto hace más de un mes que no sucedía .....algo es algo , y a ver cuánto dura 😉

Brokers destacados